Structure and modeling in the design of β- And γ-secretase inhibitors

Drug Development Research

Volumn 70, Issue 2, 2009, Pages 70-93

  Holloway, M Katharine ^a   Hunt, Peter ^b   McGaughey, Georgia B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

secretase; ; secretase; Alzheimer's disease; BACE 1; Structure based design

Indexed keywords

ASPARTIC PROTEINASE; BEGACESTAT; BETA SECRETASE INHIBITOR; BMS 299897; CATHEPSIN D; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GSI 953; MEMBRANE PROTEIN; MK 560; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; OM99 2; RENIN; TARENFLURBIL; UNCLASSIFIED DRUG; WO 04100958; WO 05023772; WO 06045554; WO 06061136; WO 2006008558; WO 2006043064; WO 2007054739;

ALZHEIMER DISEASE; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 64349124929     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20291     Document Type: Article

References (186)

1. Albert JS, Blomberg N, Breeze AL, Brown AJ, Burrows JN, Edwards PD, Folmer RH, Geschwindner S, Griffen EJ, Kenny PW, Nowak T, Olsson LL, Sanganee H, Shapiro AB. 2007. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 7:1600-1629.
2. Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. 2004. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J Am Chem Soc 126:15495-15503.
3. Åqvist J, Marelius J. 2001. The linear interaction energy method for predicting ligand binding free energies. Comb Chem High Throughput Screen 4:613-626.
4. Asberom T, Bara TA, Clader JW, Greenlee WJ, Guzik HS, Josien HB, Li W, Parker EM, Pissarnitski DA, Song L, et al. 2007a. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors. Bioorg Med Chem Lett 17:205-207.
5. Asberom T, Zhao Z, Bara TA, Clader JW, Greenlee WJ, Hyde LA, Josien HB, Li W, McPhail AT, Nomeir AA, et al. 2007b. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. Bioorg Med Chem Lett 17:511-516.
6. Avram S, Milac AL, Mihailescu DF, Dabu A, Flonta ML. 2006. Computer-aided drug design applied to beta and gamma secretase inhibitors: perspectives for new Alzheimer disease therapy. Curr Enzyme Inhib 2:311-328.
7. Barazza A, Gotz M, Cadamuro SA, Goettig P, Willem M, Steuber H, Kohler T, Jestel A, Reinemer P, Renner C, et al. 2007. Macrocyclic statine-based inhibitors of BACE-1. Chembiochem 8:2078-2091.
8. Barrow JC, Stauffer SR, Rittle KE, Ngo PL, Yang ZQ, Selnick HG, Graham SL, Munshi S, McGaughey GB, Holloway MK, et al. 2008. Discovery and X-ray crystallographic analysis of a spiropi-peridine iminohydantoin inhibitor of γ-secretase. J Med Chem 51:6259-6262.
9. Barrow JC, Rittle KE, Ngo PL, Selnick HG, Graham SL, Pitzenberger SM, McGaughey GB, Colussi D, Lai MT, Huang Q, et al. 2007. Design and synthesis of 2,3,5-substituted imidazolidin-4-one inhibitors of BACE-1. ChemMedChem 2:995-999.
10. Barten DM, Meredith Jr JE, Zaczek R, Houston JG, Albright CF. 2006. g-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R&D 7:87-97.
11. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, et al. 2007. 2-Amino-3,4- dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 50:4261-4264.
12. Bennet BD, Babu-Kahn S, Loeloff R, Louis J-C, Curran E, Citron M, Vassar R. 2000. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275:20647-20651.
13. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B. 2006. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96:732-742.
14. Bhisetti GR, Saunders JO, Murcko MA, Lepre CA, Britt SD, Come JH, Deninger DD, Wang T (Vertex Pharmaceuticals Incorporated, USA). Assignee. 2002. Preparation of b-carbolines and other inhibitors of BACE-1 aspartic proteinase useful against Alzheimer's and other BACE-mediated diseases. WO patent 2002088101.
15. Brady SF, Singh S, Crouthamel MC, Holloway MK, Coburn CA, Garsky VM, Bogusky M, Pennington MW, Vacca JP, Hazuda D, et al. 2004. Rational design and synthesis of selective BACE-1 inhibitors. Bioorg Med Chem Lett 14:601-604.
16. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. 2007. Forecasting the global burden of Alzheimer's. Alzheimer's Dement 3:186-191.
17. Broutin P-EFX, Laporte V, Lincoln CM, Carr JA, Mullan M, Bakshi P. 2006. Novel g-secretase transition state analogs as Ab inhibitors. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, March 26-30, 2006:MEDI-158.
18. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. 2001. BACE1 is the major b-secretase for generation of Ab peptides by neurons. Nature Neurosci 4:233-234.
19. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasamudram T, Bilcer G, Ghosh AK, et al. 2004. In vivo inhibition of Ab production by memapsin 2 (b-secretase) inhibitors. J Neurochem 89:1409-1416.
20. Chen SH, Lamar J, Guo D, Kohn T, Yang HC, McGee J, Timm D, Erickson J, Yip Y, May P, et al. 2004. P3 cap modified Phe*-Ala series BACE inhibitors. Bioorg Med Chem Lett 14:245-250.
21. Chou K-C. 2004. Insights from modeling the tertiary structure of human BACE2. J Proteome Res 3:1069-1072.
22. Chou KC, Howe WJ. 2002. Prediction of the tertiary structure of the beta-secretase zymogen. Biochem Biophys Res Commun 292:702-708.
23. Churcher I, Beher D. 2005. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 11:3363-3382.
24. Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, et al. 2006. 4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors. Bioorg Med Chem Lett 16:280-284.
25. Coburn CA, Stachel SJ, Li YM, Rush DM, Steele TG, Chen-Dodson E, Holloway MK, Xu M, Huang Q, Lai MT, et al. 2004. Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 47:6117-6119.
26. Coburn CA, Stachel SJ, Jones KG, Steele TG, Rush DM, DiMuzio J, Pietrak BL, Lai MT, Huang Q, Lineberger J, et al. 2006. BACE-1 inhibition by a series of ψ[CH2NH] reduced amide isosteres. Bioorg Med Chem Lett 16:3635-3638.
27. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, Chopra R, Cowling R, Ellingboe JW, Fan KY, et al. 2006. Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 49:6158-6161.
28. Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jennings LD, et al. 2008. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 18:1063-1066.
29. Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA, Chessari G, Cowan S, Edwards PD, Frederickson M, et al. 2007. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 50:1124-1132.
30. Cumming JN, Iserloh U, Kennedy ME. 2004. Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Dev 7:536-556.
31. de Strooper B, Marjaux E. 2004. γ-Secretase inhibitors: still in the running as Alzheimer's therapeutics. Drug Discovery Today: Therapeut Strat 1:1-6.
32. de Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. 1998. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390.
33. DeLano WL. 2002. The PyMOL molecular graphics system. Palo Alto, CA: DeLano Scientific.
34. Deng Y, Tarassishin L, Kallhoff V, Peethumnongsin E, Wu L, Li YM, Zheng H. 2006. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. J Neurosci 26:3845-3854.
35. Durham TB, Shepherd TA. 2006. Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Dev 9:776-791.
36. Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, Campbell JB, Carr RA, Chessari G, Congreve M, et al. 2007. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 50:5912-5925.
37. Ehehalt R, Michel B, De Pietri Tonelli D, Zacchetti D, Simons K, Keller P. 2002. Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. Biochem Biophys Res Commun 293:30-37.
38. Fechner U, Franke L, Renner S, Schneider P, Schneider G. 2003. Comparison of correlation vector methods for ligand-based similarity searching. J Comput Aided Mol Des 17:687-698.
39. Felsenstein K, Smith DW, Poss MA, Chaturvedula P, Sloan CP (Bristol-Myers Squibb Company, USA). Assignee. 1997. Preparation of 5-amino-6-cyclohexyl-4- hydroxyhexanamide derivatives as inhibitors of beta-amyloid protein production for the treatment of Alzheimer's disease. EP patent 778266.
40. Feuston B, Holloway MK, McGaughey G, Culberson JC. 2008. Virtual fragment scanning: current trends, applications and web based tools. In: Zartler ER, Shapiro MJ, editors. In Silico Design Fragment-Based Drug Discovery. A Practical Approach. Hoboken, NJ: Wiley. p 223-244.
41. Fobare WF, Solvibile WR, Robichaud AJ, Malamas MS, Manas E, Turner J, Hu Y, Wagner E, Chopra R, Cowling R, et al. 2007. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 17:5353-5356.
42. Freskos JN, Fobian YM, Benson TE, Bienkowski MJ, Brown DL, Emmons TL, Heintz R, Laborde A, McDonald JJ, Mischke BV, et al. 2007a. Design of potent inhibitors of human beta-secretase. Part 1. Bioorg Med Chem Lett 17:73-77.
43. Freskos JN, Fobian YM, Benson TE, Moon JB, Bienkowski MJ, Brown DL, Emmons TL, Heintz R, Laborde A, McDonald JJ, et al. 2007b. Design of potent inhibitors of human beta-secretase. Part 2. Bioorg Med Chem Lett 17:78-81.
44. Fujimoto T, Matsushita Y, Gouda H, Yamaotsu N, Hirono S. 2008. In silico multi-filter screening approaches for developing novel beta-secretase inhibitors. Bioorg Med Chem Lett 18:2771-2775.
45. Furnham N, Ruffle S, Southan C. 2004. Splice variants: a homology modeling approach. Proteins 54:596-608.
46. Garino C, Tomita T, Pietrancosta N, Laras Y, Rosas R, Herbette G, Maigret B, Quelever G, Iwatsubo T, Kraus JL. 2006. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 49:4275-4285.
47. Geerts H. 2007. Drug evaluation: (R)-flurbiprofen: an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs 10:121-133.
48. Geschwindner S, Olsson LL, Albert JS, Deinum J, Edwards PD, de Beer T, Folmer RH. 2007. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J Med Chem 50:5903-5911.
49. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, et al. 2001. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44:2865-2868.
50. Ghosh AK, Kumaragurubaran N, Hong L, Lei H, Hussain KA, Liu CF, Devasamudram T, Weerasena V, Turner R, Koelsch G, et al. 2006. Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta- secretase) inhibitors. J Am Chem Soc 128:5310-5311.
51. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, Weerasena V, Turner R, Koelsch G, Bilcer G, et al. 2007. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem 50:2399-2407.
52. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, Reddy DS, Weerasena V, Turner R, Chang W, et al. 2008. Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18:1031-1036.
53. Gorfe AA, Caflisch A. 2005. Functional plasticity in the substrate binding site of beta-secretase. Structure 13:1487-1498.
54. Gralle M, Oliveira CL, Guerreiro LH, McKinstry WJ, Galatis D, Masters CL, Cappai R, Parker MW, Ramos CH, Torriani I, et al. 2006. Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. J Mol Biol 357:493-508.
55. Guo T, Hobbs DW. 2006. Development of BACE1 inhibitors for Alzheimer's disease. Curr Med Chem 13:1811-1829.
56. Guo T, Gu H, Hobbs DW, Rokosz LL, Stauffer TM, Jacob B, Clader JW. 2007. Design, synthesis, and evaluation of tetrahy- droquinoline and pyrrolidine sulfonamide carbamates as gamma- secretase inhibitors. Bioorg Med Chem Lett 17:3010-3013.
57. Hamada Y, Igawa N, Ikari H, Ziora Z, Nguyen JT, Yamani A, Hidaka K, Kimura T, Saito K, Hayashi Y, et al. 2006. beta- Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 16:4354-4359.
58. Hamada Y, Abdel-Rahman H, Yamani A, Nguyen JT, Stochaj M, Hidaka K, Kimura T, Hayashi Y, Saito K, Ishiura S, et al. 2008a. BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. Bioorg Med Chem Lett 18:1649-1653.
59. Hamada Y, Ohta H, Miyamoto N, Yamaguchi R, Yamani A, Hidaka K, Kimura T, Saito K, Hayashi Y, Ishiura S, et al. 2008b. Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett 18:1643-1647.
60. Hanessian S, Yun H, Hou Y, Yang G, Bayrakdarian M, Therrien E, Moitessier N, Roggo S, Veenstra S, Tintelnot-Blomley M, et al. 2005. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomi-metics. J Med Chem 48:517551-517590.
61. Hanessian S, Yang G, Rondeau JM, Neumann U, Betschart C, Tintelnot-Blomley M. 2006. Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease beta-site amyloid precursor protein cleaving enzyme (BACE). J Med Chem 49:4544-4567.
62. Haniu M, Denis P, Young YM, EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, Katta V, et al. 2000. Characterization of Alzheimer's b-Secretase Protein BACE: A pepsin family member with unusual properties. J Biol Chem 275:21099-21106.
63. Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185.
64. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
65. Harrison B, Kreft A, Alimardanov A, Antane M, Aschmies S, Atchison K, Casebier D, Chlenov M, Cole DC, Comery T, et al. 2006. Design and synthesis of potent gamma secretase inhibitors for the disease-modifying treatment of Alzheimer's Disease. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006:MEDI-288.
66. Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, et al. 2003. BACE1 (b-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci 24:646-655.
67. Henricson A, Kall L, Sonnhammer EL. 2005. A novel transmem- brane topology of presenilin based on reconciling experimental and computational evidence. FEBS J 272:2727-2733.
68. Hills ID, Vacca JP. 2007. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Dev 10:383-391.
69. Holloway MK. 1998. A priori prediction of ligand affinity by energy minimization. Perspect. Drug Discovery Des. 9/10/11(3D QSAR in Drug Design: Ligand/Protein Interactions and Molecular Similarity):63-84.
70. Holloway MK, Wai JM, Halgren TA, Fitzgerald PM, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ, deSolms SJ. 1995. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 38:305-317.
71. Holloway MK, Culberson JC, Shpungin J, Munshi S, Coburn CA, Stachel SJ, Jones KG, Loutzenhiser E, Gregro AR, Lai M-T, et al. 2004. Evaluating scoring functions for docking and designing b-secretase inhibitors. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004: COMP-024.
72. Holloway MK, Feuston BP, McGaughey GB. 2005. Inhibiting flap up BACE? Gordon Research Conference on Computer-Aided Drug Design, July 31-August 5, 2005, Tilton, NH.
73. Holloway MK, McGaughey GB, Coburn CA, Stachel SJ, Jones KG, Stanton EL, Gregro AR, Lai MT, Crouthamel MC, Pietrak BL, et al. 2007. Evaluating scoring functions for docking and designing beta-secretase inhibitors. Bioorg Med Chem Lett 17:823-827.
74. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, Davis DL, Gailunas AF, Thorsett ED, Sinha S, et al. 2003. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 46:1799-1802.
75. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, et al. 2004. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 47:158-164.
76. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. 2000. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290:150-153.
77. Hu B, Fan KY, Bridges K, Chopra R, Lovering F, Cole D, Zhou P, Ellingboe J, Jin G, Cowling R, et al. 2004. Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors. Bioorg Med Chem Lett 14:3457-3460.
78. Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, Yang HC, Mendel D, May PC, Shapiro M, et al. 2003. Design and synthesis of statine-containing BACE inhibitors. Bioorg Med Chem Lett 13:4335-4339.
79. Huang D, Caflisch A. 2004. Efficient evaluation of binding free energy using continuum electrostatics solvation. J Med Chem 47:5791-5797.
80. Huang D, Luthi U, Kolb P, Cecchini M, Barberis A, Caflisch A. 2006. In silico discovery of beta-secretase inhibitors. J Am Chem Soc 128:5436-5443.
81. Hunt P, Wrigley JD, Shearman M, Beher D, Lewis H, Ellis S, Selway J, Clarke E, Ecclestone T, Nunn E, et al. 2006. Subtle changes in substrate presentation may explain both pathogenesis and therapeutic modulation of g-secretase. Target Specific Seminars in Drug Discovery, IBC Drug Discovery Series April 24-26, 2006; Berlin, Germany.
82. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, et al. 1999. Identification of a novel aspartic protease (Asp 2) as b-Secretase. Mol Cell Neurosci 14:419-127.
83. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, et al. 2007. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 100:802-809.
84. Hyland LJ, Tomaszek Jr TA, Meek TD. 1991. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30:8454-8463.
85. Iserloh U, Pan J, Stamford AW, Kennedy ME, Zhang Q, Zhang L, Parker EM, McHugh NA, Favreau L, Strickland C, et al. 2008a. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg Med Chem Lett 18:418-422.
86. Iserloh U, Wu Y, Cumming JN, Pan J, Wang LY, Stamford AW, Kennedy ME, Kuvelkar R, Chen X, Parker EM, et al. 2008b. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 18:414-417.
87. Isoo N, Sato C, Miyashita H, Shinohara M, Takasugi N, Morohashi Y, Tsuji S, Tomita T, Iwatsubo T. 2007. Abeta42 overproduction associated with structural changes in the catalytic pore of gamma-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate. J Biol Chem 282:12388-12396.
88. Jelley RA, Elliott J, Gibson KR, Harrison T, Beher D, Clarke EE, Lewis HD, Shearman M, Wrigley JD. 2006. 3-Substituted gem- cyclohexane sulfone based gamma-secretase inhibitors for Alzhei-mer's disease: conformational analysis and biological activity. Bioorg Med Chem Lett 16:3839-3842.
89. Jennings LD, Cole DC, Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R, Jin G, Manas ES, Fan KY, Malamas MS, et al. 2008. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket. Bioorg Med Chem Lett 18:767-771.
90. Jozwiak K, Krzysko KA, Bojarski L, Gacia M, Filipek S. 2008. Molecular models of the interface between anterior pharynx- defective protein 1 (APH-1) and presenilin involving GxxxG motifs. ChemMedChem 3:627-634.
91. Kaether C, Haass C, Steiner H. 2006. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 3:275-283.
92. Kolossvary I, Keserü GM. 2001. Hessian-free low-mode conforma- tional search for large-scale protein loop optimization: application to c-jun N-terminal kinase JNK3. J Comp Chem 22:21-30.
93. Kopcho LM, Ma J, Marcinkeviciene J, Lai Z, Witmer MR, Cheng J, Yanchunas J, Tredup J, Corbett M, Calambur D, et al. 2003. Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. Arch Biochem Biophys 410:307-316.
94. Kornacker MG, Lai Z, Witmer M, Ma J, Hendrick J, Lee VG, Riexinger DJ, Mapelli C, Metzler W, Copeland RA. 2005. An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. Biochemistry 44:11567-11573.
95. Kornilova AY, Kim J, Laudon H, Wolfe MS. 2006. Deducing the transmembrane domain organization of presenilin-1 in gamma- secretase by cysteine disulfide cross-linking. Biochemistry 45:7598-7604.
96. Kortum SW, Benson TE, Bienkowski MJ, Emmons TL, Prince DB, Paddock DJ, Tomasselli AG, Moon JB, LaBorde A, TenBrink RE. 2007. Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1. Bioorg Med Chem Lett 17:3378-3383.
97. Kuglstatter A, Stahl M, Peters JU, Huber W, Stihle M, Schlatter D, Benz J, Ruf A, Roth D, Enderle T, et al. 2008. Tyramine fragment binding to BACE-1. Bioorg Med Chem Lett 18:1304-1307.
98. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW and others. 2008. Substrate-targeting gamma-secretase modulators. Nature 453:925-929.
99. Lamar J, Hu J, Bueno AB, Yang HC, Guo D, Copp JD, McGee J, Gitter B, Timm D, May P, et al. 2004. Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg Med Chem Lett 14:239-243.
100. Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. 2006. Electron microscopic structure of purified, active gamma- secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA 103:6889-6894.
101. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, et al. 2000. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-694.
102. Liao YF, Wang BJ, Hsu WM, Lee H, Liao CY, Wu SY, Cheng HT, Hu MK. 2007. Unnatural amino acid-substituted (hydroxyethyl) urea peptidomimetics inhibit gamma-secretase and promote the neuronal differentiation of neuroblastoma cells. Mol Pharmacol 71:588-601.
103. Limongelli V, Marinelli L, Cosconati S, Braun HA, Schmidt B, Novellino E. 2007. Ensemble-docking approach on BACE-1:pharmacophore perception and guidelines for drug design. ChemMedChem 2:740.
104. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. 2000. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97:1456-1460.
105. Lindsley SR, Moore KP, Rajapakse HA, Selnick HG, Young MB, Zhu H, Munshi S, Kuo L, McGaughey GB, Colussi D, et al. 2007. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 17:4057-4061.
106. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. 2001. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neurosci 4:231-232.
107. Maillard MC, Hom RK, Benson TE, Moon JB, Mamo S, Bienkowski M, Tomasselli AG, Woods DD, Prince DB, Paddock DJ, et al. 2007. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 50:776-781.
108. McGaughey GB, Colussi D, Graham SL, Lai MT, Munshi SK, Nantermet PG, Pietrak B, Rajapakse HA, Selnick HG, Stauffer SR, et al. 2007. Beta-secretase (BACE-1) inhibitors:accounting for 10 s loop flexibility using rigid active sites. Bioorg Med Chem Lett 17:1117-1121.
109. McGaughey GB, Holloway MK. 2007. Structure-guided design of b-secretase (BACE-1) inhibitors. Expert Opin Drug Discov 2:1129-1138.
110. Moitessier N, Therrien E, Hanessian S. 2006. A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors. J Med Chem 49:5885-5894.
111. Morohashi Y, Kan T, Tominari Y, Fuwa H, Okamura Y, Watanabe N, Sato C, Natsugari H, Fukuyama T, Iwatsubo T, et al. 2006. C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N- (3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 281:14670-14676.
112. Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, Pipkorn R, Schaefer M, Langosch D, Multhaup G. 2007. GxxxG motifs within the amyloid precursor protein transmem- brane sequence are critical for the etiology of Abeta42. EMBO J 26:1702-1712.
113. Murray CW, Callaghan O, Chessari G, Cleasby A, Congreve M, Frederickson M, Hartshorn MJ, McMenamin R, Patel S, Wallis N. 2007. Application of fragment screening by X-ray crystallography to beta-secretase. J Med Chem 50:1116-1123.
114. Nadin A, Owens AP, Castro JL, Harrison T, Shearman MS. 2003. Synthesis and gamma-secretase activity of APP substrate-based hydroxyethylene dipeptide isosteres. Bioorg Med Chem Lett 13:37-41.
115. Narlawar R, Perez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K. 2006. Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem 49:7588-7591.
116. Narlawar R, Perez Revuelta BI, Baumann K, Schubenel R, Haass C, Steiner H, Schmidt B. 2007. N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase. Bioorg Med Chem Lett 17:176-182.
117. Neri M, Cascella M, Micheletti C. 2005. The influence of conformational fluctuations on enzymatic activity: modelling the functional motion of b-secretase. J Phys Condens Matter 17:S1581-S1593.
118. Ogura T, Mio K, Hayashi I, Miyashita H, Fukuda R, Kopan R, Kodama T, Hamakubo T, Iwatsubo T, Tomita T, et al. 2006. Three-dimensional structure of the gamma-secretase complex. Biochem Biophys Res Commun 343:525-534.
119. Okochi M, Fukumori A, Jiang J, Itoh N, Kimura R, Steiner H, Haass C, Tagami S, Takeda M. 2006. Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem 281:7890-7898.
120. Ostermann N, Eder J, Eidhoff Uea. 2006. Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. J Mol Biol 355:249-261.
121. Park H, Lee S. 2003. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc 125:16416-16422.
122. Park H, Min K, Kwak HS, Koo KD, Lim D, Seo SW, Choi JU, Platt B, Choi DY. 2008. Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. Bioorg Med Chem Lett 18:2900-2904.
123. Patel S, Vuillard L, Cleasby A, Murray CW, Yon J. 2004. Apo and inhibitor complex structures of BACE (beta-secretase). J Mol Biol 343:407-416.
124. Pietrancosta N, Quelever G, Garino C, Laras Y, Burlet S, Kraus J-L. 2005. Identification of privileged scaffolds from a diversified chemical library for g-secretase inhibition. Lett Drug Design Discov 2:595-600.
125. Pissarnitski D, Zhao Z, Asberom T, Bara T, Clader JW, Greenlee WJ, Guzik H, Hyde L, Josien H, Li W, et al. 2006. Cyclic sulfonamides as γ-secretase inhibitors for the treatment of Alzheimer's disease. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, September 10-14, 2006:MEDI-287.
126. Pissarnitski DA, Asberom T, Bara TA, Buevich AV, Clader JW, Greenlee WJ, Guzik HS, Josien HB, Li W, McEwan M, et al. 2007. 2,6-Disubstituted N-arylsulfonyl piperidines as gamma- secretase inhibitors. Bioorg Med Chem Lett 17:57-62.
127. Polgár T, Keserü GM. 2005. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. J Med Chem 48:3749-3755.
128. Polgar T, Keserü GM. 2006. Ensemble docking into flexible active sites. Critical evaluation of FlexE against JNK-3 and beta- secretase. J Chem Inf Model 46:1795-1805.
129. Polgár T, Magyar C, Simon I, Keserü GM. 2007. Impact of ligand protonation on virtual screening against beta-secretase (BACE1). J Chem Inf Model 47:2366-2373.
130. Prasad CV, Zheng M, Vig S, Bergstrom C, Smith DW, Gao Q, Yeola S, Polson CT, Corsa JA, Guss VL, et al. 2007. Discovery of (S)-2-((S)-2-(3,5- difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)- 3-methyl-4-oxo-4,5-dihydro-3H- benzo[d][1,2]diazepin-5-yl)propan- amide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. Bioorg Med Chem Lett 17:4006-4011.
131. Pu J, Resnick L, Aschmies S, Atchison K, Berkowitz J, Caggiano TJ, Chlenov M, Diamantidis G, Harrison B, Hu Y, et al. 2007. Synthesis of small molecule g-secretase inhibitors for Alzheimer's disease. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007:MEDI-306.
132. Rajamani R, Reynolds CH. 2004a. Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity. Bioorg Med Chem Lett 14:4843-4846.
133. Rajamani R, Reynolds CH. 2004b. Modeling the protonation states of the catalytic aspartates in beta-secretase. J Med Chem 47:5159-5166.
134. Rajapakse HA, Nantermet PG, Selnick HG, Munshi S, McGaughey GB, Lindsley SR, Young MB, Lai MT, Espeseth AS, Shi XP, et al. 2006. Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 49:7270-7273.
135. Ramsden N, Wilson F, Reid A, Reader V, Miller W, Harrison RJ, Sunose M, Hernandez-Perni R, Major J, Boussard C, et al. (Cellzome AG, Germany). Assignee. 2006. Biphenyl-carboxylic acids and derivatives thereof and their preparations, pharmaceutical compositions, g-secretase-modulating activity, and use in therapy and treatment of Alzheimer's disease. WO patent 2006021441.
136. Rishton GM, LaBonte K, Williams AJ, Kassam K, Kolovanov E. 2006. Computational approaches to the prediction of blood-brain barrier permeability: a comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr Opin Drug Discov Dev 9:303-313.
137. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, et al. 2001. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Human Mol Genet 10:1317-1324.
138. Rojo I, Martin JA, Broughton H, Timm D, Erickson J, Yang HC, McCarthy JR. 2006. Macrocyclic peptidomimetic inhibitors of b-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. Bioorg Med Chem Lett 16:191-195.
139. Sammi T, Silakari O, Ravikumar M. 2008. Three-dimensional quantitative structure-activity relationship modeling of gamma- secretase inhibitors using molecular field analysis. Chem Biol Drug Des 71:155-166.
140. Sato C, Morohashi Y, Tomita T, Iwatsubo T. 2006. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci 26:12081-12088.
141. Sauder JM, Arthur JW, Dunbrack Jr RL. 2000. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. J Mol Biol 300:241-248.
142. Saunders AJ, Kim T-W, Tanzi RE. 1999. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate down syndrome region of chromosome 21. Science 286:1255a.
143. Scott JP, Lieberman DR, Beureux OM, Brands KM, Davies AJ, Gibson AW, Hammond DC, McWilliams CJ, Stewart GW, Wilson RD, et al. 2007. A practical synthesis of a gamma- secretase inhibitor. J Org Chem 72:4149-4155.
144. Shaw D, Best J, Dinnell K, Nadin A, Shearman M, Pattison C, Peachey J, Reilly M, Williams B, Wrigley J, et al. 2006. 3,4-Fused cyclohexyl sulfones as gamma-secretase inhibitors. Bioorg Med Chem Lett 16:3073-3077.
145. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL. 2000. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 39:8698-8704.
146. Shi XP, Chen E, Yin KC, Na S, Garsky VM, Lai MT, Li YM, Platchek M, Register RB, Sardana MK, et al. 2001. The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J Biol Chem 276:10366-10373.
147. Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. 2008. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Mol Cell Biol 28:3663-3671.
148. Shuto D, Kasai S, Kimura T, Liu P, Hidaka K, Hamada T, Shibakawa S, Hayashi Y, Hattori C, Szabo B, et al. 2003. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethyl- carbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 13:4273-4276.
149. Sidera C, Liu C, Austen B. 2002. Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. BMC Biochem 3:25.
150. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537-540.
151. Spasic D, Tolia A, Dillen K, Baert V, De Strooper B, Vrijens S, Annaert W. 2006. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem 281:26569-26577.
152. Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, et al. 2004. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 47:6447-6450.
153. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, et al. 2006. Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem 49:6147-6150.
154. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Ellis J, et al. 2007. Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid. J Med Chem 50:3431-3433.
155. Stauffer SR, Stanton MG, Gregro AR, Steinbeiser MA, Shaffer JR, Nantermet PG, Barrow JC, Rittle KE, Collusi D, Espeseth AS, et al. 2007. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation. Bioorg Med Chem Lett 17:1788-1792.
156. Takahashi Y, Fuwa H, Kaneko A, Sasaki M, Yokoshima S, Koizumi H, Takebe T, Kan T, Iwatsubo T, Tomita T, et al. 2006. Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett 16:3813-3816.
157. Tanahashi H, Tabira T. 2001. Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta- peptide production. Neurosci Lett 307:9-12.
158. Tang BL, Liou YC. 2007. Novel modulators of amyloid-beta precursor protein processing. J Neurochem 100:314-323.
159. Thompson LA, Liauw AY, Ramanjulu MM, Kasireddy-Polam P, Mercer SE, Maduskuie TP, Glicksman M, Roach AH, Meredith JE, Liu RQ, et al. 2006. Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett 16:2357-2363.
160. Tolia A, Chavez-Gutierrez L, De Strooper B. 2006. Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. J Biol Chem 281:27633-27642.
161. Toulokhonova L, Metzler WJ, Witmer MR, Copeland RA, Marcinkeviciene J. 2003. Kinetic studies on beta-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. J Biol Chem 278:4582-4589.
162. Tounge BA, Reynolds CH. 2003. Calculation of the binding affinity of beta-secretase inhibitors using the linear interaction energy method. J Med Chem 46:2074-2082.
163. Tounge BA, Rajamani R, Baxter EW, Reitz AB, Reynolds CH. 2006. Linear interaction energy models for beta-secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms. J Mol Graph Model 24:475-484.
164. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V. 2002. Design of substrate-based inhibitors of human beta-secretase. J Med Chem 45:259-262.
165. Turner 3rd RT, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, Tang J. 2001. Subsite specificity of memapsin 2 (beta- secretase): implications for inhibitor design. Biochemistry 40:10001-10006.
166. Turner RT, Hong L, Koelsch G, Ghosh AK, Tang J. 2005. Structural locations and functional roles of new subsites S-5, S-6, and S-7 in memapsin 2 (b-secretase). Biochemistry 44:105-112.
167. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. 1999. β-Secretase cleavage of alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741.
168. Vidal P, Timm D, Broughton H, Chen SH, Martin JA, Rivera- Sagredo A, McCarthy JR, Shapiro MJ, Espinosa JF. 2005. Preorganization of the hydroxyethylene dipeptide isostere: the preferred conformation in solution resembles the conformation bound to BACE. J Med Chem 48:7623-7627.
169. Villaverde MC, Gonzalez-Louro L, Sussman F. 2007. The search for drug leads targeted to the b-secretase: an example of the roles of computer assisted approaches in drug discovery. Curr Topics Med Chem 7:980-990.
170. Wang Y, Zhang Y, Ha Y. 2006. Crystal structure of a rhomboid family intramembrane protease. Nature 444:179-180.
171. Wang Y-X, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, Kaufman JD, Kiso Y, Torchia DA. 1996. Solution NMR evidence that the HIV- 1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 35:9945-9950.
172. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216.
173. Winum J-Y, Scozzafava A, Montero J-L, Supuran CT. 2006. Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev 26:767-792.
174. Wolfe MS, Xia W, Moore CL, Leatherwood DD, Ostaszewski B, Rahmati T, Donker IO, Selkoe DJ. 1999a. Peptidomimetic probes and molecular modelling suggest that Alzheimer's g-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38:4720-4727.
175. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. 1999b. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513-517.
176. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, et al. 2004. Chronic treatment with the gamma-secretase inhibitor LY- 411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882.
177. Xiao K, Li X, Li J, Ma L, Hu B, Yu H, Fu Y, Wang R, Ma Z, Qiu B, et al. 2006. Design, synthesis, and evaluation of Leu*Ala hydroxyethylene-based non-peptide beta-secretase (BACE) inhibitors. Bioorg Med Chem 14:4535-4551.
178. Xie D, Gulnik S, Collins L, Gustchina E, Suvorov L, Erickson JW. 1997. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. Biochemistry 36:16166-16172.
179. Xiong B, Huang X-Q, Shen L-l, Shen J-H, Luo X-M, Shen X, Jiang H-l, Chen K-X. 2004. Conformational flexibility of b-secretase: Molecular dynamics simulation and essential dynamics analysis. Acta Pharmacol Sinica 25:705-713.
180. Yamazaki T, Nicholson LK, Torchia DA, Wingfield P, Stahl SJ, Kaufman JD, Eyermann CJ, Hodge CN, Lam PYS, Ru Y, et al. 1994. NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor. J Am Chem Soc 116:10791-10792.
181. Yang MG, Shi J-L, Modi DP, Wells J, Cochran BM, Wolf MA, Thompson LA, Ramanjulu MM, Roach AH, Zaczek R, et al. 2007. Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent γ-secretase inhibitors. Bioorg Med Chem Lett 17:3910-3915.
182. Yang W, Lu W, Lu Y, Zhong M, Sun J, Thomas AE, Wilkinson JM, Fucini RV, Lam M, Randal M, et al. 2006. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. J Med Chem 49:839-842.
183. Yu N, Hayik SA, Wang B, Liao N, Reynolds CH, Merz Jr KM. 2006. Assigning the protonation states of the key aspartates in b- secretase using QM/MM X-ray structure refinement. J Chem Theory Comput 2:1057-1069.
184. Zhou S, Zhou H, Walian PJ, Jap BK. 2007. Regulation of gamma-secretase activity in Alzheimer's disease. Biochemistry 46:2553-2563.
185. Zuo Z, Luo X, Zhu W, Shen J, Shen X, Jiang H, Chen K. 2005. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Bioorg Med Chem 13:2121-2131.
186. Zuo Z, Gang C, Zou H, Mok PC, Zhu W, Chen K, Jiang H. 2007. Why does beta-secretase zymogen possess catalytic activity? Molecular modeling and molecular dynamics simulation studies. Comput Biol Chem 31:186-195.